The aim of this study is to describe the real-world clinical profile, treatment patterns, and guideline alignment of patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan in routine clinical practice in Romania. The study uses secondary use of data, with all analyses conducted on anonymized, pre-existing data collected for routine clinical and administrative purposes.
Study Type
OBSERVATIONAL
Enrollment
500
Novartis
Bucharest, Romania
Percentage of Patients Receiving all Four Guideline-recommended Therapeutic Classes for HFrEF
The four guideline-recommended therapeutic classes include sacubitril/valsartan, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Time frame: Up to approximately 5 years and 6 months
Percentage of Patients by Demographic Category
Demographics include age group and sex.
Time frame: Up to approximately 5 years and 6 months
Percentage of Patients by Clinical Characteristic Category
Clinical characteristics include treating physician specialty, diagnosis, comorbidities, and concomitant medications.
Time frame: Up to approximately 5 years and 6 months
Percentage of Patients Who Used Angiotensin-converting Enzyme (ACE) Inhibitors and/or Angiotensin Receptor Blockers Before Starting Sacubitril/Valsartan Treatment
Time frame: Up to approximately 5 years and 6 months
Percentage of Patients by Sacubitril/Valsartan Prescribed Dose at Treatment Initiation
Time frame: Baseline
Percentage of Patients by Dosing Frequency
Time frame: Up to approximately 5 years and 6 months
Duration of Sacubitril/Valsartan Treatment
Time frame: Up to approximately 5 years and 6 months
Percentage of Patients by Use of Individual Guideline-recommended Pharmacological Therapeutic Classes for HFrEF
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Guideline-recommended pharmacological therapeutic classes for HFrEF include beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors.
Time frame: Up to approximately 5 years and 6 months
Percentage of Patients by Most Frequently Prescribed Concomitant Cardiovascular Medications
Time frame: Up to approximately 5 years and 6 months
Number of Concomitant Cardiovascular Medications
Time frame: Up to approximately 5 years and 6 months